What type of study is this?

This is a Cohort Study study (also classified as: Case Report).

October 18, 2025Open Access

Infliximab-Induced Organizing Pneumonia Resulting in Persistent Respiratory Impairment

Key Points

Significant respiratory impairment was observed in patients treated with infliximab, linking it to organizing pneumonia.
Infliximab, which inhibits TNF cytokine signaling, may lead to severe pulmonary toxicity and persistent respiratory issues.
Previous case reports reveal acute pulmonary toxicity patterns, yet the long-term effects remain poorly characterized.
This paper highlights the need for further examination of infliximab's extended impacts on lung function.

Abstract

ABSTRACT Infliximab is a biologic agent used to treat moderate-to-severe ulcerative colitis by inhibiting the TNF cytokine signaling. Off-target effects of TNF inhibitors include immune suppression and disruption of the tissue repair response. Previous case reports have linked infliximab to several patterns of acute pulmonary toxicity; however, the potential for severe infliximab-induced pneumonitis on long-term respiratory impairment remains largely uncharacterized.

Infliximab-Induced Organizing Pneumonia Resulting in Persistent Respiratory Impairment

Key Points

Abstract

Cite This Study

Also Consider

Also Consider